Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,922.60 +583.63 (+0.87%) CMC Crypto 200
1,375.49 +44.88 (+3.38%)
CSL Limited (CMXHF)
| Previous close | 206.25 |
| Open | 201.21 |
| Bid | 193.00 x 2900 |
| Ask | 207.00 x 2900 |
| Day's range | 201.21 - 201.21 |
| 52-week range | 144.81 - 206.65 |
| Volume | |
| Avg. volume | 1,225 |
| Market cap | 101.336B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 39.53 |
| EPS (TTM) | 5.09 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | 2.46 (1.27%) |
| Ex-dividend date | 11 Mar 2024 |
| 1y target est | N/A |
ZacksGMAB vs. CSLLY: Which Stock Is the Better Value Option?
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
CNW GroupCSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
CSL Behring Canada Inc., a business unit of global biotechnology leader CSL, today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) recommended public drug plan reimbursement for HEMGENIX® (etranacogene dezaparvovec) for the treatment of eligible adults with hemophilia B (congenital factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. The recommendation is based on resul
PR NewswireCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
CSL Seqirus, a business of CSL (ASX: CSL), today announced that it has commenced shipping its differentiated portfolio of influenza vaccines. This year, the company's influenza vaccines are being produced as trivalent influenza vaccine (TIV) formulations, in compliance with the U.S. Food and Drug Administration's (FDA) directive to remove the B/Yamagata strain.4
